Press Releases Investors Overview News / Events Overview Press Releases Publications IR Calendar Analyst Coverage Email Alerts Company Info Overview Management Team Clinical Advisory Board Medical Consultants Presentations Contacts FAQ Financial Info Overview Balance Sheet Income Statement Cash Flow Financial Results Stock Data Quote Charts Historical Data SEC Filings Overview All SEC Filings Annual Reports Quarterly Reports Section 16 Filings Governance Overview Board of Directors Board Committees Governance Documents Investor Tools Email Alerts Tear Sheet Investor Presentation Contacts RSS News Feed News / Events Overview Press Releases Publications IR Calendar Analyst Coverage Email Alerts All Years 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 All Releases Financial Releases Viveve Announces FDA Approval to Conduct PURSUIT Trial for Improvement of Stress Urinary Incontinence Jul 7, 2020 Viveve Medical Announces Adjournment of Annual Meeting Jun 29, 2020 Viveve Reports First Quarter 2020 Financial Results and Provides Corporate Update May 14, 2020 Viveve to Host Conference Call to Provide Corporate Update and First Quarter 2020 Financial Results on May 14, 2020 May 7, 2020 Viveve Announces Update to Corporate Strategy Apr 17, 2020 Viveve Announces Exercise of Warrants for $3 Million Gross Proceeds Apr 17, 2020 Viveve Announces Approval of Viveve 2.0 System in Canada Apr 16, 2020 Viveve Resubmits U.S. Investigational Device Exemption to FDA to Conduct New PURSUIT Trial for Improvement of Stress Urinary Incontinence Apr 15, 2020 Viveve Announces Topline Results from Pivotal U.S. VIVEVE II Trial for Improvement of Sexual Function in Women Apr 9, 2020 Viveve Announces Clearance of Next Generation 2.0 System in Taiwan Mar 26, 2020 1 2 3 4 5 6 7 8 9 10 ...31
Viveve Announces FDA Approval to Conduct PURSUIT Trial for Improvement of Stress Urinary Incontinence Jul 7, 2020
Viveve to Host Conference Call to Provide Corporate Update and First Quarter 2020 Financial Results on May 14, 2020 May 7, 2020
Viveve Resubmits U.S. Investigational Device Exemption to FDA to Conduct New PURSUIT Trial for Improvement of Stress Urinary Incontinence Apr 15, 2020
Viveve Announces Topline Results from Pivotal U.S. VIVEVE II Trial for Improvement of Sexual Function in Women Apr 9, 2020
